CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Sotera Health Q3 revenue beats estimates on pricing and volume

By Reuters News


Overview

  • US sterilization services provider's Q3 revenue rose 4.4% yr/yr, beating analyst expectations

  • Adjusted EPS for Q3 increased 12%, beating analyst expectations

  • Company reaffirmed full-year 2026 revenue and adjusted EBITDA growth outlook


Outlook

  • Sotera Health sees 2026 net revenues at $1.233 bln to $1.250 bln, up 5.25%-6.75%

  • Company expects 2026 adjusted EBITDA of $632 mln to $641 mln, up 5.75%-7.25%

  • Sotera Health maintains 2026 adjusted EPS outlook at $0.95 to $1.01


Result Drivers

  • PRICING AND VOLUME - Co said Q3 revenue growth was driven by higher pricing, improved volume and mix, and foreign currency benefit

  • HARVEST TIMING - Co said Nordion segment revenue declined due to expected timing of Cobalt-60 harvest schedules

  • PRODUCTIVITY AND PRICING - Segment income margin benefited from operational productivity and favorable pricing, partially offset by inflation


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$324.89 mln

$319.77 mln (10 Analysts)

Q3 Adjusted EPS

Beat

$0.29

$0.27 (10 Analysts)

Q3 Net Income

$58.39 mln

Q3 Pretax Profit

Miss

$83.73 mln

$101.37 mln (8 Analysts)

Q3 Gross Profit

$180.79 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Sotera Health Company is $23.25, about 31.1% above its November 2 closing price of $17.74

  • The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 18 three months ago


Reuters Recommended Reads

  • Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook

  • Nov 3 - Stevanato Group Q3 revenue beats estimates on biopharma segment

  • Nov 3 - Revvity Q3 revenue beats estimates, raises FY guidance


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.